Read transcripts of debates in both Houses
Produced by Commons Library, Lords Library and Parliamentary Office Science and Technology
Search for Members by name, postcode, constituency and party
Learn about their experience, knowledge and interests
Celebrating people who have made Parliament a positive, inclusive working environment
Four staff networks for people to discuss and consider issues.
Contact your MP or a Member of the House of Lords about an issue that matters to you
Sign up for the Your Parliament newsletter to find out how you can get involved
Take a tour of Parliament and enjoy a delicious afternoon tea by the River Thames
See some of the sights you’ll encounter on a tour of Parliament
Book a school visit, classroom workshop or teacher-training session
Access videos, worksheets, lesson plans and games
Follow this EDM by:
That this House is concerned by the preliminary guidance given by the National Institute for Health and Clinical Excellence on Alimta, the drug used in the treatment of mesothelioma cancer caused by exposure to asbestos; is aware of the wide geographical variation in the availability of the drug and that the Scottish Medicines Consortium and the London Cancer New Drugs Group have already approved the use of Alimta; notes that initial results suggest it has been successful in increasing life expectancy and improving the quality of life of patients; supports the Trades Union Congress in its view that the estimated impact on the NHS of £3 million in the current year and around £5 million by the end of the decade is a small cost to pay for treatment that makes such a difference; and urges that Alimta be made universally available for the treatment of mesothelioma in the UK.
Total number of signatures: 79
Showing 79 out of 79